Core Viewpoint - The Hong Kong Innovative Drug ETF Penghua (159286) experienced a 2.37% increase in value on October 16, with a trading volume of 217 million yuan, indicating positive market sentiment towards innovative drug investments [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 562 million yuan [1] - The fund's shares increased by 7 million to a total of 594 million shares, with a notable increase of 98 million shares over the past 20 trading days [1] - Since its inception on August 20, 2025, the fund has reported a return of -5.38%, while the return over the past month is -7.86% [1] Group 2: Management and Benchmark - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index return (adjusted for exchange rates) [1]
10月16日港股创新药ETF鹏华（159286）份额增加700.00万份，最新份额5.94亿份，最新规模5.62亿元
Xin Lang Cai Jing·2025-10-17 02:58